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Abstract
Background—Alcohol has particularly harmful health effects in HIV-infected patients; 
therefore, HIV clinics are an important setting for integration of brief alcohol intervention and 
alcohol pharmacotherapy to improve patient outcomes. Current practices of alcohol screening, 
counseling, and prescription of pharmacotherapy by HIV providers are unknown.
Methods—We conducted a cross-sectional survey of HIV providers from 8 HIV clinical sites 
across the United States. Surveys queried knowledge and use of alcohol screening, brief advice, 
counseling and pharmacotherapy, confidence and willingness to prescribe pharmacotherapy and 
barriers to their use of alcohol pharmacotherapy. We used multivariable logistic regression to 
examine provider factors associated with confidence and willingness to prescribe 
pharmacotherapy.
Results—Providers (N=158) were predominantly female (58%) and Caucasian (73%); almost 
half were infectious disease physicians and 31% had been in practice 10–20 years. Most providers 
(95%) reported always or usually screening for alcohol use, although only 10% reported using a 
formal screening tool. Over two-thirds never or rarely treated alcohol-dependent patients with 
pharmacotherapy themselves. Most (71%) referred alcohol-dependent patients for treatment. 
Knowledge regarding alcohol pharmacotherapy was low. The major barrier to prescribing 
pharmacotherapy was insufficient training on use of pharmacotherapy. Provider confidence ratings 
were positively correlated with their practice patterns.
Conclusions—HIV providers reported high rates of screening for alcohol use, though few used 
a formal screening tool. Most providers referred alcohol dependent patients to outside resources 
for treatment. Few reported prescribing alcohol pharmacotherapy. Increased training alcohol 
pharmacotherapy may increase confidence in prescribing and use of these medications in HIV care 
settings.
Keywords
HIV; Alcohol Screening; Education; Confidence; Knowledge
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1. INTRODUCTION
Alcohol misuse includes a spectrum of severity, from hazardous/risky use, defined as a 
“quantity or pattern of alcohol consumption that places patients at risk for adverse health 
events” which includes binge drinking, to alcohol abuse and/or dependence that result in 
adverse physical and psychological health effects (Reid et al., 1999). Alcohol misuse is 
prevalent among HIV-infected individuals, and is associated with decreased antiretroviral 
therapy uptake, adherence, and virologic suppression (Galvan et al., 2002; Samet et al., 
2004; Braithwaite et al., 2005; Chander et al., 2006, 2008). Unfortunately, patient 
engagement and retention in traditional alcohol treatment services is poor in both HIV-
infected and uninfected persons. Across the life span, fewer than 15% of persons with 
alcohol misuse ever receive any kind of formal alcohol treatment (Office of Applied Studies, 
2009). To address this gap, screening and brief alcohol intervention (SBI) has been 
developed and tested for delivery in primary care and emergency room settings and has been 
shown to reduce alcohol misuse and improve health-related outcomes (Kaner et al., 2009). 
Brief alcohol intervention and motivational interviewing based interventions have also been 
effective in reducing alcohol use in HIV care settings (Hasin et al., 2013; Chander et al., 
2015).
In addition to SBI, there are several FDA-approved pharmacotherapies with demonstrated 
efficacy in reducing alcohol consumption. A recent systematic review and meta-analysis 
(Jonas et al., 2014) of 122 randomized controlled trials highlighted the effectiveness of these 
therapies. Yet fewer than one in five alcohol treatment clinics offers alcohol 
pharmacotherapy to their patients (Ducharme et al., 2006). To broaden engagement and 
retention in treatment, there has been considerable interest in trying to move alcohol services 
into main stream medical practice in a model similar to that adopted for treatment of 
depression. However, despite a good evidence base for both SBI and alcohol 
pharmacotherapy for the treatment of alcohol misuse, these interventions also remain 
underused in primary care settings (Jonas et al., 2014).
Given the particularly harmful effects of alcohol misuse in HIV-infected patients, HIV 
clinics are an important setting for integration of SBI and alcohol pharmacotherapy. They 
provide long-term care to their patients, integrate a variety of specialty services, frequently 
have expanded funding for prescription medications, and often provide intensive case 
management models that promote outreach to and retention of patients. However, there are 
barriers to integration of alcohol screening, counseling and pharmacotherapy into HIV care, 
including increased demands on already busy providers, and lack of training on and 
familiarity with alcohol pharmacotherapy.
Given the potential benefits of reducing alcohol misuse among HIV-infected patients, the 
aims of the current study were to: 1) characterize current practice patterns related to alcohol 
screening, advice, counseling and pharmacotherapy; 2) examine providers’ knowledge, 
attitudes and beliefs about these alcohol interventions; and 3) identify HIV provider barriers 
to prescribing alcohol pharmacotherapy for HIV infected patients. The goal of this study was 
to inform the development of strategies to facilitate implementation of alcohol interventions 
in HIV primary care clinics.
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2. MATERIAL AND METHODS
2.1 Study design
This was a cross-sectional survey of HIV providers across the United States. The survey was 
administered between January, 2013 and March, 2014.
2.2 Participants
Participants included attending physicians, fellows, medical residents, nurse practitioners, 
and physician assistants working in 8 HIV clinics. The selected sites are part of the Center 
for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS), including 
University of Alabama, Birmingham; University of Washington, Seattle; University of 
California San Francisco; Harvard University Fenway Clinic, Boston; Johns Hopkins 
University, Baltimore; University of California, San Diego; Case Western Reserve Hospital, 
Cleveland; and University of North Carolina, Chapel Hill. A list of provider email contact 
information was provided by each clinic.
2.3 Survey
The composition of the survey was largely based on prior research by Harris and Sun 
(2012), the Physician’s Competence in Substance Abuse Test (PCSAT) and Alford and 
colleagues (2008); items were added to specifically assess alcohol pharmacotherapy, a 
primary focus of our study. The survey addressed four areas of alcohol intervention: 
screening, brief advice, counseling and pharmacotherapy. Across these four areas, providers 
were asked to report on their current practice patterns and their confidence and willingness 
to engage in each intervention type. In addition, the survey included 17 knowledge items on 
alcohol interventions and 4 items specifically addressing potential barriers to their use of 
alcohol pharmacotherapy. Items were answered using Likert scales; scale anchors were 
modified according to the nature of the item. For example, practice items were rated on a 5-
point Likert scale (i.e., never, rarely, sometimes, usually, always). Knowledge items were 
rated on a 7-point Likert scale from “strongly disagree” to “strongly agree”, with the center 
of the scale anchored by “Don’t Know.” Willingness and confidence items were rated on a 
10-point Likert scale from not at all to extremely. Barriers to use of alcohol 
pharmacotherapy were rated on a 5-point scale from not a barrier to very major barrier.
This survey was designed and conducted prior to the launch of the American Psychiatric 
Association Diagnostic and Statistical Manual 5 (APA DSM 5), and therefore used the terms 
alcohol abuse and dependence, the diagnostic nomenclature of DSM IV. In the survey, items 
on referral to alcohol treatment and pharmacotherapy referenced patients with alcohol abuse 
or dependence. Items on the use of brief advice and counseling referenced patients with 
hazardous/risky drinking, that is, persons with a quantity or pattern of alcohol consumption 
that places patients at risk for adverse health events.
The survey was intended to be ten minutes in length and providers could elect to receive a 
$10 gift card for their participation. This study was approved by the JHU Institutional 
Review Board (IRB) and the IRBs at the study sites. The introduction to the survey assured 
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participants that their responses were anonymous and data would not be provided back to the 
clinic directors. Completion of the survey served as consent for participation.
2.4 Survey Distribution
Within 2 weeks preceding survey distribution, clinic directors sent out an email to their 
provider network informing them of the upcoming survey and encouraging participation. An 
email inviting survey participation was sent to a total of 269 HIV/primary care providers 
across the 8 CNICS sites. Each provider’s email included a unique link to access an 
electronic survey hosted by Survey Monkey. Reminder emails were sent approximately 2, 4, 
and 6 weeks following the initial survey distribution.
2.5 Analysis Plan
We performed descriptive statistics to describe screening and treatment practices and 
confidence in screening, providing advice, counseling, and prescribing pharmacotherapy. We 
then conducted multivariable logistic regression analysis examining key provider 
characteristics associated with greater confidence (visual analog scale (VAS) >5)) and 
greater willingness (VAS >5) to prescribe pharmacotherapy. Provider characteristics 
included sex, provider type (i.e., Infectious Disease, Family Practice/Internist, and Physician 
Extender: Physician Assistant or Nurse Practitioner, Medical Resident/Fellow), years in 
practice, and hours of prior training in the management of alcohol use disorders (i.e., <10, 
≥10, none/don’t remember) and study site. We then used multivariable logistic regression 
analysis to examine factors associated with self-reported prescription of pharmacotherapy 
for dependence, including provider type, confidence and willingness to prescribe, years in 
practice, prior training, and site. Several CNICS sites (n=6) use a tablet-based clinical 
assessment tool that includes the AUDIT-C; therefore, we also examined whether provider-
reported use of a formal screening tool varied in clinics with and without the tool.
3. RESULTS
3.1 Provider characteristics
Of the 269 HIV providers who received an email invitation, 158 participants completed the 
survey. Response rates varied across CNICS sites, and ranged from 29% to 95% of 
distributed surveys. The overall electronic response rate across sites was 58.7%. Compared 
to the total sample who received a survey, respondents did not differ significantly by sex/
gender or provider type.
As summarized in Table 1, providers reported a median age of 42, were predominantly 
female (58%), and Caucasian (73%). Over half of the respondents were attending physicians 
(63%) and 19% were physicians in residency or fellowship training. An additional 18% were 
nurse practitioners or physician assistants. Overall, this was a highly experienced group of 
practitioners, with 31% in practice 10 – 20 years and 23% in practice 21 years and more. 
Two-thirds of the providers (66%) reported less than 10 training hours related to alcohol 
problems during their medical/nursing/post-graduate education. Twenty eight percent of 
respondents were from the Mid-Atlantic, 34% from the West, 27% from the South, and the 
remaining 11% were from New England, and the Mid-West.
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3.2 Current practice behaviors
As shown in Figure 1A, the majority of providers reported usually or always screening for 
alcohol use among new patients. Specifically, 74% of providers reported always and an 
additional 21% reported usually asking new patients whether they drink alcohol. 
Approximately half of providers reported always asking new patients about their drinking 
frequency (56%) and intensity (46%) (drinks per drinking day), and an additional one-third 
or more of providers reported usually asking these questions. Few providers (10%) reported 
always or usually using a formal screening tool to assess alcohol use. This estimate did not 
differ between providers practicing at clinic sites using tablet-based clinical assessments 
(n=109), and those that did not (n=49).
In addition to screening for alcohol use, providers also reported providing advice about 
drinking (Figure 1B). One-quarter always or usually provided advice on safer drinking limits 
to patients who drink but do not have alcohol problems. For patients with hazardous 
drinking, over two-thirds (69%) of providers reported always or usually recommending that 
the patient cut-down and 25% recommended alcohol abstinence. For patients with alcohol 
dependence, 80% of providers always or usually recommended cutting down and 72% 
recommended abstinence (Figure 1C). While providers tended to provide advice on drinking 
reduction to patients, they were less likely to treat those with dependence. Over two-thirds of 
providers (71%) reported rarely or never treating alcohol dependent patients themselves, and 
instead reported referring their alcohol-dependent patients for treatment. Three-quarters had 
not prescribed a medication to support alcohol abstinence in the past year (data not shown).
3.3 Willingness and confidence as a function of intervention type
Most providers expressed confidence (VAS > 5) in their skills at taking an alcohol history 
(90%), assessing a patient’s risk for developing alcohol-related problems (74%), using a 
formal alcohol screening tool (69%), advising patients regarding safe drinking limits (83%), 
and counseling patients about hazardous alcohol use (86%).
In contrast, only 16% reported confidence in prescribing alcohol pharmacotherapy for their 
patients with alcohol dependence; although one-third of providers indicated a willingness 
(VAS > 5) to prescribe these medications. Providers rated four potential barriers to their use 
of alcohol pharmacotherapy (Figure 2). The only item rated by most providers (72%) as a 
major or very major barrier was insufficient training on how to use medications in 
individuals with alcohol dependence. In contrast, 10% of providers rated inadequate 
research on medication efficacy, 1% rated concerns about offending patients, and 29% rated 
lack of insurance as major or very major barriers to their use of pharmacotherapy.
3.4 Knowledge items on alcohol interventions
Responses on knowledge items were evaluated for incorrect and don’t know responses. 
Overall, providers were familiar with definitions of binge drinking for men and women 
(>80% correctly identifying ≥4 drinks/occasion in women and ≥5 drinks/occasion in men as 
binge drinking), brief advice and counseling; however, the majority of participants were not 
knowledgeable about alcohol pharmacotherapy. Eighty-eight percent of respondents 
answered “don’t know” (65%) or incorrectly (23%) to a statement indicating that 
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acamprosate was contraindicated in individuals with liver impairment, and 76% of 
respondents marked “don’t know” to a statement indicating that there was no benefit to 
naltrexone if initial pharmacotherapy with acamprosate was not successful. Finally, 34% of 
providers answered don’t know (27%) or incorrectly (7%) to a statement indicating that 
disulfiram is the preferred treatment if a patient wants to continue drinking but at reduced 
levels. After combining these three pharmacotherapy knowledge questions, 8% of 
individuals answered all three questions correctly.
3.5 Relationship between provider characteristics and alcohol pharmacotherapy ratings
In multivariable analysis (Table 2), family practitioners and general internists reported 
greater confidence in prescribing alcohol medications than infectious disease providers 
(OR=8.18, (95% CI=2.26 –29.58)). Providers with 10 – 20 years in practice reported higher 
confidence in prescribing alcohol medications than those with fewer than 10 years in 
practice (OR=5.72 p=0.041 (95% CI=1.08 – 30.35)). There also was a trend for hours of 
alcohol-related training to predict confidence, with those reporting more than 10 training 
hours reporting greater confidence than providers with fewer than 10 training hours (OR= 
3.67 p= 0.078 (95% CI=0.89 – 15.05)). There were no differences in confidence ratings 
across sites or for male and female providers.
There were no significant differences in willingness to prescribe pharmacotherapy by 
provider type, sex, years in practice or prior training in the treatment of AUD. However, 
though not statistically significant, providers with 10 – 20 hours of alcohol-related training 
reported greater willingness to prescribe compared to those with less than 10 hours (OR= 
2.67, p=0.07 (95% CI=0.90 – 7.91)).
3.6 Predictors of alcohol pharmacotherapy prescribing practices
Twenty four percent of the sample reported prescribing pharmacotherapy for alcohol use in 
the prior 12 months (naltrexone, acamprosate, disulfiram, or ondansetron). Family 
physicians and internists were more likely to prescribe pharmacotherapy compared to 
infectious disease doctors in multivariable analysis (OR: 3.20; 95% CI: 1.12–9.15, p=0.030) 
adjusted for sex, years in practice, prior training in the management of alcohol use and site. 
In separate multivariable analyses including either confidence or willingness to prescribe 
pharmacotherapy, confidence (VAS >5) (OR:33.7; 95% CI:8.89–128.21, p<0.001) and 
willingness to prescribe pharmacotherapy (VAS >5) (OR: 6.69;95% CI:2.70–16.58, p=0 
<0.001) were most strongly associated with self-reported prescription of pharmacotherapy 
after adjusting for provider type, years in practice, prior training and site.
4. DISCUSSION
In this sample of HIV providers, 95% reported always or usually screening new patients for 
alcohol use, and over 2/3 offered advice to their hazardous drinking patients. In contrast, 
providers in general reported low knowledge of alcohol pharmacotherapy; few providers 
reported prescribing alcohol pharmacotherapy in the past year, and most referred their 
alcohol dependent patients to outside resources for treatment. Provider confidence ratings 
were positively correlated with their practice patterns; that is, participants rated their 
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confidence high in those practice areas that they engaged in most frequently. In the area of 
alcohol pharmacotherapy, providers reported very low confidence and perceived a high need 
for additional training in this area.
Findings for this sample of HIV providers are in line with those reported for providers in 
other types of medical settings in terms of successful integration of alcohol screening and 
advice for hazardous/risky drinkers, but lower rates of implementation of alcohol counseling 
and pharmacotherapy for alcohol dependent patients (Mark et al., 2009a; Oslin et al., 2014). 
This likely reflects the perception of primary care providers that alcohol dependence 
requires subspecialty treatment, as this has been the predominant model of care to date.
While providers reported routinely screening for alcohol use, it was notable that few 
reported using a formal screening tool for identifying alcohol misuse. This has important 
implications for the management of alcohol misuse in HIV clinical settings as the use of a 
screening tool such as the AUDIT-C has been found to be more sensitive to detection of 
alcohol use compared to quantity/frequency questions (Fiellin et al., 2000). Furthermore, in 
the Veteran’s Administration (VA) setting, where universal screening has been 
systematically implemented, patient self-administered AUDIT-C improved reporting of 
alcohol use, compared to provider/staff administered AUDIT-C (Hawkins et al., 2007). This 
was explored in a follow-up qualitative study, where investigators found that when asking 
the questions verbally, AUDIT-C questions were adapted, suggested responses were implied, 
or questions were omitted (Williams et al., 2015). Use of the single item screen (Smith et al., 
2009), “How many times in the past year have you had five (four for women) or more drinks 
in a day” or the AUDIT-C verbatim, may increase detection of alcohol misuse and result in 
more opportunities to intervene in HIV clinics. In addition, the AUDIT-C can provide 
normative data on severity of use, which may further guide treatment decisions.
In this sample, provider knowledge of alcohol pharmacotherapy was low, with the majority 
of providers answering “don’t know” to questions related to the use of naltrexone and 
acamprosate for alcohol dependence. These findings are consistent with past studies of 
alcohol pharmacotherapy, where low provider knowledge has been noted to be a significant 
barrier to use of these medications (Mark et al., 2003; Harris et al., 2013). In the current 
study, several provider characteristics were related to self-reported confidence to prescribe 
alcohol pharmacotherapy. Specifically, both higher years in practice and hours of alcohol-
related training were associated with greater confidence to prescribe. Family practitioners 
and general internists were more confident than ID providers about prescribing alcohol 
pharmacotherapy but provider type did not influence self-reported willingness to prescribe.
These findings are of high importance. Training hours is a modifiable characteristic and thus 
may represent the primary target for changing providers’ attitudes and behaviors. Alcohol 
pharmacotherapy training materials are already available through a variety of resources and 
in a variety of formats. The other provider characteristic that was related to confidence and 
willingness to prescribe was years in practice. The more senior providers may represent 
practitioners in the HIV care setting who would be most likely to help lead change in 
prescribing patterns within the practice. For example, research has supported the 
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effectiveness of identifying change and/or opinion leaders as a strategy for facilitating 
changes in provider practices (Flodgren et al., 2011; Mostofian et al., 2015).
Our results are similar to those recently reported by Montague and colleagues (Montague et 
al., 2015). In their study, HIV providers (N=159) also reported moderate to high levels of 
confidence in their abilities to assess and monitor patients with heavy/hazardous drinking 
patterns, and lower confidence in their ability to effectively manage alcohol treatment needs 
on-site in the HIV clinic. A strength of the current report is that providers were sampled 
nationwide, whereas Montague et al limited their sample to providers in New England. Thus 
our study extends findings outside of the New England region, to the Mid-Atlantic, South 
and West. In addition, survey response rate was higher in this current study than in the 
Montague study (58% vs. 3%).
A variety of Federal and professional agencies, including the U.S. Preventive Services Task 
Force (USPTF), have recommended routine alcohol screening in adult patients and the 
provision of brief behavioral counseling for persons identified with heavy or hazardous 
alcohol use (Moyer, 2013). This has led to fairly wide-spread adoption of these practices 
across a variety of health care settings, including primary care sites, emergency departments, 
and Obstetrics/Gynecology services. The Affordable Care Act requires coverage for 
evidence based preventive services set forth by the USPSTF that have an evidence grade A 
or B thus integration of screening and brief intervention may increase further in HIV and 
other primary care settings. In contrast, prescription of alcohol medications by primary care 
physicians has lagged. In 2006, approximately half of all retail prescriptions for FDA-
approved alcohol pharmacotherapies were written by psychiatrists and roughly a quarter 
were written by general practitioners (Mark et al., 2009a). This low uptake is surprising 
given the wide spread prescription of antidepressants by primary care clinicians. Indeed, 
approximately 3/4 of all antidepressant prescriptions are now written by non-psychiatrists 
compared to ¼ of alcohol pharmacotherapies (Mark et al., 2009b; Mojtabai and Olfson, 
2011). Furthermore, in 2007, 720,000 retail prescriptions were filled for alcohol medications 
compared with 226 million antidepressant prescriptions (Mark et al., 2009a). This is striking 
given that there is less than a two-fold difference in the 12-month prevalence of depression 
(6.9%; Substance Abuse and Mental Health Services Administration, 2013) and alcohol 
dependence (4%; Hasin et al., 2013) in the United States.
The importance of integration of effective alcohol treatments into primary care settings is 
highlighted by results of a recent randomized controlled clinical trial by Oslin and 
colleagues (2014) comparing a primary-care based Alcohol Care Management (ACM) 
program focused on pharmacotherapy and psychosocial support with standard care in 
specialty outpatient addiction treatment services. Participants randomized to ACM were 
significantly more likely to remain in care over the 26-week trial and to reduce heavy 
drinking days, although no group difference in abstinence was observed. Results strongly 
support the potential benefits of moving alcohol care out of specialty settings and into 
mainstream health care delivery. Integrating alcohol treatment into HIV primary care 
settings also has the potential to overcome patient and system level barriers to treatment, 
including waiting time to treatment entry, lack of treatment availability, privacy and alcohol 
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dependence-related stigma (Redko et al., 2006; Rapp et al., 2006; Carr et al., 2008; 
Schomerus et al., 2011).
There are limitations to this study. First, responses were based on self-report, and may 
reflect some social desirability bias, though all respondents were all informed that surveys 
were confidential. Second, though our survey was based on the Physicians’ Competence in 
Substance Abuse Test (P-CSAT), a measure with established reliability and validity, we 
modified the P-CSAT by adding items on pharmacotherapy without conducting further 
psychometric assessment of the revised instrument. Third, our results may underestimate use 
of a screening tool. Low reported use of formal alcohol screening may be due in part to the 
providers’ ability to access the tablet- based clinical assessments which are available 6 of the 
8 sites. Finally, though we sampled providers from several sites across the United States, 
these sites our not representative of all sites of HIV care. Furthermore, our response rate was 
58%, and thus findings may not be representative of all HIV providers and may be subject to 
non-respondent bias.
Our findings indicate that overall alcohol screening and advice has been integrated into HIV 
care settings; however, wide spread adoption of the use of alcohol pharmacotherapy is more 
challenging as a result of providers’ lack of knowledge, training and confidence. Our 
findings strongly support the need for additional provider training as well as other provider 
support strategies and systems to encourage use of alcohol medications.
Acknowledgments
Role of Funding Source: This research was funded by the National Institute of Alcohol Abuse and Alcoholism 
NIAAA U24AA020801 (McCaul, Chander, Monroe, Hutton), NIAAA U01 (Saag, Cropsey) and NIAAA U01 
(Crane, Kitahata), K23MH105284-01 (Monroe) and the CFAR Network of Integrated Clinical Systems (R24 
AI0667039)
The authors would like to acknowledge Dr. Richard Saitz who provided survey materials used in the development 
of this project.
References
Alford DP, Richardson JM, Chapman SE, Dubé CE, Schadt RW, Saitz R. A web-based Alcohol 
Clinical Training (ACT) curriculum: Is in-person faculty development necessary to affect teaching? 
BMC Med Educ. 2008; 8:11. [PubMed: 18325102] 
Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Cook RL, Gordon A, 
Bridges MW, Seiler JF. A temporal and dose- response association between alcohol consumption 
and medication adherence among veterans in care. Alcohol Clin Exp Res. 2005; 29:1190–1197. 
[PubMed: 16046874] 
Carr CJ, Xu J, Redko C, Lane DT, Rapp RC, Goris J, Carlson RG. Individual and system influences on 
waiting time for substance abuse treatment. J Subst Abuse Treat. 2008; 34:192–201. [PubMed: 
17512159] 
Chander G, Josephs J, Fleishman J, Korthuis P, Gaist P, Hellinger J, Gebo K. Alcohol use among HIV- 
infected persons in care: results of a multi-site survey. HIV Med. 2008; 9:196–202. [PubMed: 
18366443] 
Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of 
suppression in HIV infection. J Acquir Immune Defic Syndr. 2006; 43:411. [PubMed: 17099312] 
Chander G, Hutton HE, Lau B, Xu X, McCaul ME. Brief Intervention decreases drinking frequency in 
HIV-infected, heavy drinking women: tesults of a randomized controlled trial. J Acquir Immune 
Defic Syndr. 2015; 70:137–145. [PubMed: 25967270] 
Chander et al. Page 10
Drug Alcohol Depend. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ducharme LJ, Knudsen HK, Roman PM. Trends in the adoption of medications for alcohol 
dependence. J Clin Psychopharmacol. 2006; 26(Suppl 1):S13–19. [PubMed: 17114950] 
Fiellin DA, Reid MC, O’Connor PG. Screening for alcohol problems in primary care: a systematic 
review. Arch Intern Med. 2000; 160:1977–1989. [PubMed: 10888972] 
Flodgren G, Parmelli E, Doumit G, Gattellari M, O’Brien MA, Grimshaw J, Eccles MP. Local opinion 
leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 
2011:CD000125. [PubMed: 21833939] 
Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, Longshore D, Morton SC, 
Orlando M, Shapiro M. The prevalence of alcohol consumption and heavy drinking among people 
with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud 
Alcohol. 2002; 63:179–186. [PubMed: 12033694] 
Harris AH, Ellerbe L, Reeder RN, Bowe T, Gordon AJ, Hagedorn H, Oliva E, Lembke A, Kivlahan D, 
Trafton JA. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action 
strategies among Veterans Health Administration service providers. Psychol Serv. 2013; 10:410. 
[PubMed: 23356858] 
Harris JM, Sun H. The Physicians’ Competence in Substance Abuse Test (P-CSAT): a 
multidimensional educational measurement tool for substance abuse training programs. Drug 
Alcohol Depend. 2012; 122:236–240. [PubMed: 22055011] 
Hasin DS, Aharonovich E, O’Leary A, Greenstein E, Pavlicova M, Arunajadai S, Waxman R, 
Wainberg M, Helzer J, Johnston B. Reducing heavy drinking in HIV primary care: a randomized 
trial of brief intervention, with and without technological enhancement. Addiction. 2013; 
108:1230–1240. [PubMed: 23432593] 
Hawkins EJ, Kivlahan DR, Williams EC, Wright SM, Craig T, Bradley KA. Examining quality issues 
in alcohol misuse screening. Subst Abuse. 2007; 28:53–65.
Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, 
Rowe CJ. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a 
systematic review and meta-analysis. JAMA. 2014; 311:1889–1900. [PubMed: 24825644] 
Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, 
Heather N. The effectiveness of brief alcohol interventions in primary care settings: Aasystematic 
review. Drug Alcohol Rev. 2009; 28:301–323. [PubMed: 19489992] 
Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence 
medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009a; 
99:345–349. [PubMed: 18819759] 
Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S. Physicians’ opinions about 
medications to treat alcoholism. Addiction. 2003; 98:617–626. [PubMed: 12751979] 
Mark TL, Levit KR, Buck JA. Psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 
2009b; 60:1167. [PubMed: 19723729] 
Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is 
growing. Health Aff. 2011; 30:1434–1442.
Montague BT, Kahler CW, Colby SM, McHugh RK, Squires D, Fitzgerald B, Operario D, Gallagher 
D, Monti PM, Mayer KH. Attitudes and training needs of New England HIV care and addiction 
treatment providers: opportunities for better integration of HIV and alcohol treatment services. 
Addict Disord Their Treat. 2015; 14:16–28. [PubMed: 25745365] 
Mostofian F, Ruban C, Simunovic N, Bhandari M. Changing physician behavior: what works? Am J 
Manag Care. 2015; 21:75–84. [PubMed: 25880152] 
Moyer VA. Screening and behavioral counseling interventions in primary care to reduce alcohol 
misuse: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 
159:210–218. [PubMed: 23698791] 
Office of Applied Studies. Alcohol Treatment: Need, Utilization, and Barriers. Substance Abuse and 
Mental Health Services Administration; Rockville, MD: 2009. 
Oslin DW, Lynch KG, Maisto SA, Lantinga LJ, McKay JR, Possemato K, Ingram E, Wierzbicki M. A 
randomized clinical trial of alcohol care management delivered in Department of Veterans Affairs 
primary care clinics versus specialty addiction treatment. J Gen Intern Med. 2014; 29:162–168. 
[PubMed: 24052453] 
Chander et al. Page 11
Drug Alcohol Depend. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rapp RC, Xu J, Carr CA, Lane DT, Wang J, Carlson R. Treatment barriers identified by substance 
abusers assessed at a centralized intake unit. J Subst Abuse Treat. 2006; 30:227–235. [PubMed: 
16616167] 
Redko C, Rapp RC, Carlson RG. Waiting time as a barrier to treatment entry: perceptions of substance 
users. J Drug Issues. 2006; 36:831–852. [PubMed: 18509514] 
Reid MC, Fiellin DA, O’Connor PG. Hazardous and harmful alcohol consumption in primary care. 
Arch Intern Med. 1999; 159:1681–1689. [PubMed: 10448769] 
Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral 
adherence among HIV- infected persons with alcohol problems. Alcohol: Clin Exp Res. 2004; 
28:572–577. [PubMed: 15100608] 
Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC. The stigma of 
alcohol dependence compared with other mental disorders: a review of population studies. Alcohol 
Alcohol. 2011; 46:105–112. [PubMed: 21169612] 
Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question 
alcohol screening test. J Gen Intern Med. 2009; 24:783–788. [PubMed: 19247718] 
Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey 
on Drug use and Health: Mental Health Findings. Substance Abuse and Mental Health Services 
Administration; Rockville, MD: 2013. 
Williams EC, Achtmeyer CE, Thomas RM, Grossbard JR, Lapham GT, Chavez LJ, Ludman EJ, 
Berger D, Bradley KA. Factors underlying quality problems with alcohol screening prompted by a 
clinical reminder in primary care: a multi-site qualitative study. J Gen Intern Med. 2015; 30:1125–
1132. [PubMed: 25731916] 
Chander et al. Page 12
Drug Alcohol Depend. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
We surveyed HIV providers on their alcohol screening and treatment practices
The majority of HIV providers report routinely screening for alcohol use, though 
fewer reported using a formal screening tool
Fewer providers provide pharmacotherapy for alcohol use
Lack of knowledge is cited as a barrier to the use of pharmacotherapy in HIV clinics
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Figure 1. 
Figure 1a, b, c. Alcohol Screening, Counseling and Treatment Practices.
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Figure 2. 
Provider Barriers to the Use of Alcohol Pharmacotherapy
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Table 1
Provider Demographics Characteristics (N=158)
Variable n (%)*
Age
 Median 42
 Interquartile Range 36–53
Sex
 Female 91 (58)
 Male 66 (42)
 Not Reported 1 (0)
Race
 African American or Black 5 (3)
 Caucasian 115 (73)
 Asian 19 (12)
 Other 6 (4)
 Not Reported 13 (8)
Ethnicity
 Hispanic or Latino/a 10 (6)
 Not Hispanic or Latino/a 134 (85)
 Not Reported 14 (9)
Provider Type
 Family Practice Internal Medicine Attending 23 (15)
 Physician Extenders** 29 (18)
 Resident/Fellow 30 (19)
 Infectious Disease Attending 76 (48)
Years in Practice
 Less than 10 59 (37)
 10–20 49 (31)
 More than 20 37 (23)
 Not Reported 13 (8)
Training hours for alcohol problems in post-graduate school?
 Less than 10 hours 104 (66)
 More than 10 hours 18 (11)
 Do Not Remember/Not Reported 36 (23)
Geographic Location
 New England 13 (8)
 Mid-Atlantic 44 (28)
 South 43 (27)
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Variable n (%)*
 West 53 (34)
 Mid-West 5 (3)
Practice Location
 Urban 126 (80)
 Suburban 19 (12)
 Rural 1 (1)
 Not Reported 12 (8)
*
Percentages may not add to 100% due to rounding.
**
Physician Extenders are Nurse Practitioners and Physician Assistants.
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